C
Codex DNA Inc
NASDAQ:DNAY
Codex DNA Inc
NASDAQ:DNAY
Price:
2 USD
8.11%
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of DNAY.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DNAY
Relative Value
Base Case
Not Available
C
Valuation Multiples
Multiples Across Competitors
DNAY Competitors Multiples
Codex DNA Inc Competitors
Codex DNA Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Codex DNA Inc
NASDAQ:DNAY
|
59.8m USD | 2.2 | -1.2 | -0.7 | -0.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.3B USD | 5.2 | 36.9 | 22.8 | 33.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
184B USD | 4.2 | 22.8 | 16.6 | 20.4 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.5B CHF | 5.6 | 57.3 | 19.7 | 28.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.5B USD | 2.7 | 29.9 | 16.3 | 25.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.9B USD | 6.1 | 33.1 | 26.4 | 31.8 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
54.9T KRW | 14.9 | 64 | 33.7 | 48.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.9B USD | 7.1 | 34.2 | 23.9 | 26.5 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.6B USD | 9.1 | 46.9 | 32.5 | 39.5 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
25.6B USD | 3.1 | 37.4 | 16.9 | 26 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR | 7.1 | 75.4 | 32.4 | 53.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
